JP7079495B2 - Ｔｌｒ阻害性オリゴヌクレオチドおよびそれらの使用 - Google Patents

Ｔｌｒ阻害性オリゴヌクレオチドおよびそれらの使用 Download PDF

Info

Publication number
JP7079495B2
JP7079495B2 JP2018533265A JP2018533265A JP7079495B2 JP 7079495 B2 JP7079495 B2 JP 7079495B2 JP 2018533265 A JP2018533265 A JP 2018533265A JP 2018533265 A JP2018533265 A JP 2018533265A JP 7079495 B2 JP7079495 B2 JP 7079495B2
Authority
JP
Japan
Prior art keywords
seq
oligodeoxynucleotide
disease
represented
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018533265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500873A (ja
JP2019500873A5 (enExample
Inventor
永二 江指
晃司 石田
拓美 細澤
めぐみ 奥山
歩 小瀧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of JP2019500873A publication Critical patent/JP2019500873A/ja
Publication of JP2019500873A5 publication Critical patent/JP2019500873A5/ja
Application granted granted Critical
Publication of JP7079495B2 publication Critical patent/JP7079495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018533265A 2015-12-25 2016-12-22 Ｔｌｒ阻害性オリゴヌクレオチドおよびそれらの使用 Active JP7079495B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015255008 2015-12-25
JP2015255008 2015-12-25
PCT/JP2016/088418 WO2017111045A1 (en) 2015-12-25 2016-12-22 Tlr inhibitory oligonucleotides and their use

Publications (3)

Publication Number Publication Date
JP2019500873A JP2019500873A (ja) 2019-01-17
JP2019500873A5 JP2019500873A5 (enExample) 2020-02-06
JP7079495B2 true JP7079495B2 (ja) 2022-06-02

Family

ID=59090457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018533265A Active JP7079495B2 (ja) 2015-12-25 2016-12-22 Ｔｌｒ阻害性オリゴヌクレオチドおよびそれらの使用

Country Status (9)

Country Link
US (1) US10806749B2 (enExample)
EP (1) EP3394263B1 (enExample)
JP (1) JP7079495B2 (enExample)
KR (1) KR20180089531A (enExample)
CN (1) CN108431228A (enExample)
AU (1) AU2016375543A1 (enExample)
CA (1) CA3009154A1 (enExample)
IL (1) IL260193A (enExample)
WO (1) WO2017111045A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
US10350307B2 (en) * 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
CN109266732A (zh) * 2018-09-13 2019-01-25 中山大学附属第医院 TLR7和TLR8作为IgA肾病预防治疗靶点的应用及TLR7的抑制剂及其应用
CN114569722B (zh) * 2022-03-07 2022-11-22 广州市妇女儿童医疗中心 抑制血小板焦亡的试剂在制备预防和/或治疗脓毒症的药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105361A2 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JP2007533318A (ja) 2004-04-22 2007-11-22 モル リサーチ アプリケーションズ リミテッド ｃＰＬＡ２に対するアンチセンスオリゴヌクレオチド、その組成物及び使用
US20100035972A1 (en) 2008-08-06 2010-02-11 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
WO2014082254A1 (en) 2012-11-29 2014-06-05 Changchun Huapu Biotechnology Co., Ltd Inhibitory oligonucleotide and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011520A (enExample) 1973-05-31 1975-02-06
AU2003275776B2 (en) * 2002-11-08 2009-06-18 Jingang Medicine (Australia) Pty Ltd A method for optimising gene expression using synonymous codon optimisation
JP5011520B2 (ja) 2005-08-12 2012-08-29 国立大学法人 長崎大学 新規ヒト形質細胞様樹状細胞株
PL2154144T3 (pl) 2008-08-06 2015-04-30 Changchun Huapu Biotechnology Co Ltd Oligonukleotydy i ich zastosowanie
CN101696434A (zh) * 2009-10-27 2010-04-21 中国科学院过程工程研究所 β-聚苹果酸发酵新工艺
US20170240896A1 (en) * 2014-02-07 2017-08-24 Sbi Biotech, Co., Ltd. Inhibitory Oligonucleotides for Treating Tumors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007533318A (ja) 2004-04-22 2007-11-22 モル リサーチ アプリケーションズ リミテッド ｃＰＬＡ２に対するアンチセンスオリゴヌクレオチド、その組成物及び使用
WO2006105361A2 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JP2008537551A (ja) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
US20100035972A1 (en) 2008-08-06 2010-02-11 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
WO2014082254A1 (en) 2012-11-29 2014-06-05 Changchun Huapu Biotechnology Co., Ltd Inhibitory oligonucleotide and use thereof
JP2015536659A (ja) 2012-11-29 2015-12-24 Ｓｂｉバイオテック株式会社 阻害性オリゴヌクレオチド及びその使用

Also Published As

Publication number Publication date
KR20180089531A (ko) 2018-08-08
IL260193A (en) 2018-07-31
JP2019500873A (ja) 2019-01-17
AU2016375543A1 (en) 2018-06-28
CA3009154A1 (en) 2017-06-29
EP3394263A1 (en) 2018-10-31
EP3394263A4 (en) 2019-08-21
CN108431228A (zh) 2018-08-21
US20190008888A1 (en) 2019-01-10
US10806749B2 (en) 2020-10-20
EP3394263B1 (en) 2025-02-26
WO2017111045A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
KR102027023B1 (ko) 저해성 올리고뉴클레오티드 및 그의 용도
US20160355822A1 (en) Inhibitory oligonucleotides and their use in therapy
US10041076B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2014052931A1 (en) Human toll-like receptor inhibitors and methods of use thereof
EP3394263B1 (en) Tlr inhibitory oligonucleotides and their use
US20100035972A1 (en) Oligonucleotide and use thereof
CA2620582A1 (en) Methods of altering an immune response induced by cpg oligodeoxynucleotides
JP6307190B2 (ja) 阻害性オリゴヌクレオチド及びその使用
CA2638176C (en) Oligonucleotide and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190419

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191223

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20201222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220516

R150 Certificate of patent or registration of utility model

Ref document number: 7079495

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250